NCT05321875 (EARLY-GENE) is a Phase 3 clinical trial of Candesartan in Cardiomyopathy, Dilated, sponsored by Cristina Avendaño Solá.

Who is sponsoring NCT05321875?

NCT05321875 is sponsored by Cristina Avendaño Solá.

What drugs are being tested in NCT05321875?

Interventions in NCT05321875: Candesartan.

What condition does NCT05321875 study?

NCT05321875 studies Cardiomyopathy, Dilated.

Is NCT05321875 still recruiting?

NCT05321875 is currently recruiting now. Last updated 7 November 2024.

Last reviewed 2024-11-07 · How we verify

NCT05321875: EARLY-GENE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

Recruiting now Phase 3 Last updated 7 November 2024

What this trial tests

Phase 3 trial testing Candesartan in Cardiomyopathy, Dilated in 320 participants. Currently enrolling.

Timeline

2 June 2022

Primary endpoint
2 June 2026

2 June 2026

Quick facts

Lead sponsor	Cristina Avendaño Solá
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	320
Start date	2 June 2022
Primary completion	2 June 2026
Estimated completion	2 June 2026
Sites	1 location across Spain

Drugs / interventions tested

Candesartan — full drug profile →

Conditions studied

Cardiomyopathy, Dilated — all drugs for Cardiomyopathy, Dilated →

Sponsor

Cristina Avendaño Solá

Who can join

Adults 18 to 64, any sex, with Cardiomyopathy, Dilated. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic)

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations.
Sorella A, Galanti K, Iezzi L, Gallina S, et al · · 2025 · cited 13× · PMID 39674807 · DOI 10.1093/ehjqcco/qcae109
Application of next generation sequencing in cardiology: current and future precision medicine implications.
Papadopoulou E, Bouzarelou D, Tsaousis G, Papathanasiou A, et al · · 2023 · cited 6× · PMID 37424920 · DOI 10.3389/fcvm.2023.1202381
Clinical care of family members of patients with dilated cardiomyopathy.
Verdonschot JAJ, Kaski JP, Asselbergs FW, Behr ER, et al · · 2025 · cited 1× · PMID 40902100 · DOI 10.1093/eurheartj/ehaf571

Verify or expand the search:

Other trials of Candesartan

Trials testing the same drug.

NCT05328635 — Post-traumatic Headache Multidisciplinary Study · completed
NCT04606563 — Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on · Phase 3 · terminated
NCT04430959 — Candesartan as an Adjunctive Treatment for Bipolar Depression · EARLY_PHASE1 · withdrawn
NCT04351724 — Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) · Phase 2, PHASE3 · unknown
NCT04138316 — CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study · completed

Other recruiting trials for Cardiomyopathy, Dilated

Currently open trials in the same condition.

NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
NCT06091475 — Therapy to Maintain Remission in Dilated Cardiomyopathy · NA · recruiting
NCT05981092 — A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) · active not recruiting
NCT07527715 — Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy · recruiting
NCT04225520 — AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT · NA · active not recruiting

Other Cristina Avendaño Solá trials

Trials by the same sponsor.

NCT04615429 — Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS · Phase 2 · completed
NCT04345523 — Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05321875 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cristina Avendaño Solá
Last refreshed: 7 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing